A Comparison of the Pharmacokinetics and Pulmonary Lymphatic Exposure of a Generation 4 PEGylated Dendrimer Following Intravenous and Aerosol Administration to Rats and Sheep

Pharmaceutical Research

Volumn 33, Issue 2, 2016, Pages 510-525

  Ryan, Gemma M ^a   Bischof, Robert J ^a   Enkhbaatar, Perenlei ^b   McLeod, Victoria M ^a   Chan, Linda J ^a   Jones, Seth A ^a,c   Owen, David J ^c   Porter, Christopher J H ^a   Kaminskas, Lisa M ^a  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^c Starpharma Holdings Limited   (Australia)

Author keywords

lymphatic; pharmacokinetics; pulmonary; rats; sheep

Indexed keywords

DENDRIMER; NANOCARRIER; AEROSOL; DRUG CARRIER; MACROGOL DERIVATIVE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG FECES LEVEL; DRUG INSTILLATION; DRUG URINE LEVEL; FEMALE; LUNG; LYMPH VESSEL; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SHEEP; TIME TO MAXIMUM PLASMA CONCENTRATION; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE; METABOLISM; PHARMACOKINETICS; SPRAGUE DAWLEY RAT;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRAVENOUS; AEROSOLS; ANIMALS; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; LUNG; LYMPH NODES; MALE; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY; SHEEP;

EID: 84954286312     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-015-1806-z     Document Type: Article

References (48)

1. Patton JS, Fishburn CS, Weers JG. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc. 2004;1(4):338-44.
2. Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67-74.
3. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2012;64:302-15.
4. McLeod VM, Chan LJ, Ryan GM, Porter CJH, Kaminskas LM. Optimal PEGylation can improve the exposure of interferon in the lungs following pulmonary administration. J Pharm Sci. 2015;104(4):1421-30.
5. Baginski L, Gobbo OL, Tewes F, Salomon JJ, Healy AM, Bakowsky U, et al. In vitro and in vivo characterisation of PEG-lipid-based micellar complexes of salmon calcitonin for pulmonary delivery. Pharm Res. 2012;29(6):1425-34.
6. Kaminskas LM, Kota J, McLeod VM, Kelly BD, Karellas P, Porter CJH. PEGylation of polylysine dendrimers improves absorption and lymphatic targeting following SC administration in rats. J Control Release. 2009;140(2):108-16.
7. Ryan GM, Kaminskas LM, Porter CJH. Nano-chemotherapeutics: Maximising lymphatic drug exposure to improve the treatment of lymph-metastatic cancers. J Control Release. 2014.
8. Tiantian Y, Wenji Z, Mingshuang S, Rui Y, Shuangshuang S, Yuling M, et al. Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome: influence of formulation factors on the lymphatic targeting. Int J Pharm. 2014;471(1-2):245-57.
9. Liu H, Moynihan KD, Zheng Y, Szeto GL, Li AV, Huang B, et al. Structure-based programming of lymph-node targeting in molecular vaccines. Nature. 2014;507(7493):519-22.
10. Ryan GM, Kaminskas LM, Bulitta JB, McIntosh MP, Owen DJ, Porter CJH. PEGylated polylysine dendrimers increase lymphatic exposure to doxorubicin when compared to PEGylated liposomal and solution formulations of doxorubicin. J Control Release. 2013;172(1):128-36.
11. Kourtis IC, Hirosue S, de Titta A, Kontos S, Stegmann T, Hubbell JA, et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE. 2013;8(4):e61646.
12. Khullar OV, Griset AP, Gibbs-Strauss SL, Chirieac LR, Zubris KAV, Frangioni JV, et al. Nanoparticle migration and delivery of paclitaxel to regional lymph nodes in a large animal model. J Am Coll Surg. 2012;214(3):328-37.
13. Kim CK, Han JH. Lymphatic delivery and pharmacokinetics of methotrexate after intramuscular injection of differently charged liposome-entrapped methotrexate to rats. J Microencapsul. 1995;12(4):437-46.
14. Kaminskas LM, McLeod VM, Ryan GM, Kelly BD, Haynes JM, Williamson M, et al. Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy. J Control Release. 2014;183:18-26.
15. Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, et al. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm. 2008;5(3):449-63.
16. Boyd BJ, Kaminskas LM, Karellas P, Krippner G, Lessene R, Porter CJ. Cationic poly-L-lysine dendrimers: pharmacokinetics, biodistribution, and evidence for metabolism and bioresorption after intravenous administration to rats. Mol Pharm. 2006;3(5):614-27.
17. Ryan GM, Kaminskas LM, Kelly BD, Owen DJ, McIntosh MP, Porter CJH. Pulmonary administration of PEGylated polylysine dendrimers: absorption from the lung versus retention within the lung is highly size-dependent. Mol Pharm. 2013;10(8):2986-95.
18. Cryan S-A, Sivadas N, Garcia-Contreras L. In vivo animal models for drug delivery across the lung mucosal barrier. Adv Drug Deliv Rev. 2007;59(11):1133-51.
19. Abraham WM. Modeling of asthma, COPD and cystic fibrosis in sheep. Pulm Pharmacol Ther. 2008;21(5):743-54.
20. Meeusen EN, Snibson KJ, Hirst SJ, Bischof RJ. Sheep as a model species for the study and treatment of human asthma and other respiratory diseases. Drug Discov Today: Dis Model. 2009;6(4):101-6.
21. Albertine KH. Progress in understanding the pathogenesis of BPD using the baboon and sheep models. Semin Perinatol. 2013;37(2):60-8.
22. De Las Heras Guillamón M, Borderías Clau L. The sheep as a large animal experimental model in respiratory diseases research. Arch Bronconeumol. 2010;46(10):499-501.
23. Scheerlinck J-PY, Snibson KJ, Bowles VM, Sutton P. Biomedical applications of sheep models: from asthma to vaccines. Trends Biotechnol. 2008;26(5):259-66.
24. Schlesinger RB. Comparative deposition of inhaled aerosols in experimental animals and humans: a review. J Toxicol Environ Health. 1985;15(2):197-214.
25. Staub NC, Bland RD, Brigham KL, Demling R, Erdmann Iii AJ, Woolverton WC. Preparation of chronic lung lymph fistulas in sheep. J Surg Res. 1975;19(5):315-20.
26. Enkhbaatar P, Murakami K, Shimoda K, Mizutani A, Traber L, Phillips GB, et al. The iNOS inhibitor, BBS-2 prevents acute lung injury in sheep after burn and smoke inhalation injury. Am J Respir Crit Care Med. 2003;167:1021-6.
27. Caliph SM, Shackleford DM, Ascher DB, Kaminskas LM. Practical lessons in murine thoracic lymph duct cannulations: observations in female and male mice across four different strains that impact on "cannulatability". J Pharm Sci. 2015;104(3):1207-9.
28. Slatter JG, Adams LA, Bush EC, Chiba K, Daley-Yates PT, Feenstra KL, et al. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica. 2002;32(10):907-24.
29. Prankerd RJ, Nguyen T-H, Ibrahim JP, Bischof RJ, Nassta GC, Olerile LD, et al. Pulmonary delivery of an ultra-fine oxytocin dry powder formulation: potential for treatment of postpartum haemorrhage in developing countries. PLoS ONE. 2013;8(12):e82965.
30. Hershey AE, Kurzman ID, Forrest LJ, Bohling CA, Stonerook M, Placke ME, et al. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model. Clin Cancer Res. 1999;5(9):2653-9.
31. Zarogoulidis P, Chatzaki E, Porpodis K, Domvri K, Hohenforst-Schmidt W, Goldberg EP, et al. Inhaled chemotherapy in lung cancer: future concept of nanomedicine. Int J Nanomed. 2012;7:1551-72.
32. Gagnadoux F, Pape AL, Lemarié E, Lerondel S, Valo I, Leblond V, et al. Aerosol delivery of chemotherapy in an orthotopic model of lung cancer. Eur Respir J. 2005;26(4):657-61.
33. Wittgen BPH, Kunst PWA, van der Born K, van Wijk AW, Perkins W, Pilkiewicz FG, et al. Phase I study of aerosolized SLIT cisplatin in the treatment of patients with carcinoma of the lung. Clin Cancer Res. 2007;13(8):2414-21.
34. Otterson GA, Villalona-Calero MA, Sharma S, Kris MG, Imondi A, Gerber M, et al. Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs. Clin Cancer Res. 2007;13(4):1246-52.
35. Protein purification: principles, high resolution methods, and applications. 3rd ed. Janson J-C, editor: Wiley; 2012.
36. Colthorpe P, Farr SJ, Taylor G, Smith IJ, Wyatt D. The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit. Pharm Res. 1992;9(6):764-8.
37. Niven RW, Whitcomb KL, Shaner L, Ip AY, Kinstler OB. The pulmonary absorption of aerosolized and intratracheally instilled rhG-CSF and monoPEGylated rhG-CSF. Pharm Res. 1995;12(9):1343-9.
38. Codrons V, Vanderbist F, Ucakar B, Préat V, Vanbever R. Impact of formulation and methods of pulmonary delivery on absorption of parathyroid hormone (1-34) from rat lungs. J Pharm Sci. 2004;93(5):1241-52.
39. Mordenti J. Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci. 1986;75(11):1028-40.
40. Belvisi MG, Hele DJ. Animal models of cough. In: Chung FK, Boushey H, Widdicombe J, editors. Cough: causes, mechanisms and therapy: Wiley Online Library; 2007.
41. Bennett WD, Foster WM, Chapman WF. Cough-enhanced mucus clearance in the normal lung. J Appl Physiol. 1990;69(5):1670-5.
42. Hasani A, Pavia D, Agnew J, Clarke S. Regional lung clearance during cough and forced expiration technique (FET): effects of flow and viscoelasticity. Thorax. 1994;49(6):557-61.
43. van der Wal JG, Meyer JHF. Protein digestion in ruminants. S Afr J Anim Sci. 1988;18(1):30-41.
44. Chanana AD, Joel DD. The ovine bronchopulmonary lymph drainage pathways: a model to study pulmonary immune responses. Exp Lung Res. 1985;9(3-4):211-20.
45. Schraufnagel DE. Lung lymphatic anatomy and correlates. Pathophysiology. 2010;17(4):337-43.
46. Choi HS, Ashitate Y, Lee JH, Kim SH, Matsui A, Insin N, et al. Rapid translocation of nanoparticles from the lung airspaces to the body. Nat Biotechnol. 2010;28(12):1300-3.
47. Matthay MA, Berthiaume Y, Albertine KH, Grady M, Fick G. Protein clearance from the air spaces and lungs of unanesthetized sheep over 144 h. J Appl Physiol. 1989;67(5):1887-97.
48. Buchackert Y, Rummel S, Vohwinkel CU, Gabrielli NM, Grzesik BA, Mayer K, et al. Megalin mediates transepithelial albumin clearance from the alveolar space of intact rabbit lungs. J Physiol. 2012;590(Pt 20):5167-81.